{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:24:24Z","timestamp":1771550664225,"version":"3.50.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T00:00:00Z","timestamp":1385510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0080193","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T23:50:55Z","timestamp":1385596255000},"page":"e80193","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure"],"prefix":"10.1371","volume":"8","author":[{"given":"Marcus M.","family":"Schittenhelm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Illing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Figen","family":"Ahmut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina Henriette","family":"Rasp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Blumenstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles D.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin M.","family":"Kampa-Schittenhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,11,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the Light: The Growing Complexity of p53","volume":"137","author":"KH Vousden","year":"2009","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"9551","DOI":"10.1073\/pnas.1200019109","article-title":"Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors","volume":"109","author":"K Edlund","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood.V85.8.2189.bloodjournal8582189","article-title":"TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities","volume":"85","author":"H Kaneko","year":"1995","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/10428199609054848","article-title":"TP53 mutations in myelodysplastic syndrome","volume":"23","author":"S Misawa","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.leu.2401044","article-title":"RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up","volume":"12","author":"RA Padua","year":"1998","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"M Jadersten","year":"1979","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood.V74.7.2318.2318","article-title":"Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia","volume":"74","author":"Z Kelman","year":"1989","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"T Zenz","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"HG Wendel","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"FG Rucker","year":"2012","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12094-010-0460-5","article-title":"Molecular biology of therapy-related leukaemias","volume":"12","author":"M Joannides","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Haferlach T (2008) Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program: 400\u2013411.","DOI":"10.1182\/asheducation-2008.1.400"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/leu.2008.375","article-title":"The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia","volume":"23","author":"H Seifert","year":"2009","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1097-2765(01)00367-7","article-title":"ASPP Proteins Specifically Stimulate the Apoptotic Function of p53","volume":"8","author":"Y Samuels-Lev","year":"2001","journal-title":"Molecular Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1073\/pnas.0809080106","article-title":"Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds","volume":"106","author":"KM Kampa","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1101\/gad.374006","article-title":"ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth","volume":"20","author":"V Vives","year":"2006","journal-title":"Genes Dev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1080\/1042819021000040017","article-title":"Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome","volume":"43","author":"IS Lossos","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1128\/MCB.20.21.8018-8025.2000","article-title":"Proapoptotic p53-Interacting Protein 53BP2 Is Induced by UV Irradiation but Suppressed by p53","volume":"20","author":"CD Lopez","year":"2000","journal-title":"Molecular and Cellular Biology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"34473","DOI":"10.1074\/jbc.M503736200","article-title":"Control of ASPP2\/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function","volume":"280","author":"Z Zhu","year":"2005","journal-title":"J Biol Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.4161\/cc.8.16.9355","article-title":"The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin","volume":"8","author":"MM Schittenhelm","year":"2009","journal-title":"Cell Cycle"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"MM Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system","volume":"29","author":"C Rollig","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1128\/MCB.20.21.8018-8025.2000","article-title":"Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53","volume":"20","author":"CD Lopez","year":"2000","journal-title":"Mol Cell Biol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.str.2007.11.012","article-title":"Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73","volume":"16","author":"RA Robinson","year":"2008","journal-title":"Structure"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1128\/MCB.24.3.1341-1350.2004","article-title":"ASPP1 and ASPP2: common activators of p53 family members","volume":"24","author":"D Bergamaschi","year":"2004","journal-title":"Mol Cell Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.4161\/cc.8.18.9474","article-title":"New insights into the expanding complexity of the tumor suppressor ASPP2","volume":"8","author":"KM Kampa","year":"2009","journal-title":"Cell Cycle"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1073\/pnas.1201514110","article-title":"N terminus of ASPP2 binds to Ras and enhances Ras\/Raf\/MEK\/ERK activation to promote oncogene-induced senescence","volume":"110","author":"Z Wang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/cdd.2010.101","article-title":"SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence","volume":"18","author":"XD Wang","year":"2010","journal-title":"Cell Death Differ"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1074\/jbc.M110.194019","article-title":"PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ","volume":"286","author":"CY Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.cub.2010.06.024","article-title":"ASPP2 regulates epithelial cell polarity through the PAR complex","volume":"20","author":"W Cong","year":"2010","journal-title":"Curr Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.devcel.2010.06.003","article-title":"ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development","volume":"19","author":"R Sottocornola","year":"2010","journal-title":"Dev Cell"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"13325","DOI":"10.1073\/pnas.1120193109","article-title":"Autophagic activity dictates the cellular response to oncogenic RAS","volume":"109","author":"Y Wang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/cbt.7.5.5712","article-title":"Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination","volume":"7","author":"H Berglind","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"ref34","first-page":"227","article-title":"Point mutations in the conserved regions of the p53 tumour suppressor gene do not account for the transforming process in the Jurkat acute lymphoblastic leukemia T-cells","volume":"6","author":"R Laumann","year":"1992","journal-title":"Leukemia"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/sj.cdd.4401536","article-title":"Apoptosis-stimulating protein of p53-2 (ASPP2\/53BP2L) is an E2F target gene","volume":"12","author":"D Chen","year":"2005","journal-title":"Cell Death Differ"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e14524","DOI":"10.1371\/journal.pone.0014524","article-title":"DNA methylation of the first exon is tightly linked to transcriptional silencing","volume":"6","author":"F Brenet","year":"2011","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hep.23247","article-title":"Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma","volume":"51","author":"J Zhao","year":"2010","journal-title":"Hepatology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0080193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T23:06:16Z","timestamp":1597100776000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0080193"}},"subtitle":[],"editor":[{"given":"Klaus","family":"Roemer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,11,27]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,11,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0080193","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,27]]}}}